

# Simon G A Brown

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7162519/publications.pdf>

Version: 2024-02-01

89  
papers

7,010  
citations

101543

36  
h-index

58581

82  
g-index

92  
all docs

92  
docs citations

92  
times ranked

5609  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global View on Ant Venom Allergy: from Allergenic Components to Clinical Management. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 123-144.	6.5	7
2	Snakebite-associated thrombotic microangiopathy: an Australian prospective cohort study [ASP30]. <i>Clinical Toxicology</i> , 2022, 60, 205-213.	1.9	15
3	Conservative versus Interventional Treatment for Spontaneous Pneumothorax. <i>New England Journal of Medicine</i> , 2020, 382, 405-415.	27.0	164
4	Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 172, 1-8.	2.8	7
5	Markers Involved in Innate Immunity and Neutrophil Activation are Elevated during Acute Human Anaphylaxis: Validation of a Microarray Study. <i>Journal of Innate Immunity</i> , 2019, 11, 63-73.	3.8	17
6	Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock. <i>The Cochrane Library</i> , 2018, 2018, CD006312.	2.8	37
7	Serum mast cell tryptase measurements: Sensitivity and specificity for a diagnosis of anaphylaxis in emergency department patients with shock or hypoxaemia. <i>EMA - Emergency Medicine Australasia</i> , 2018, 30, 366-374.	1.1	28
8	Towards complete identification of allergens in Jack Jumper ( <i>Myrmecia pilosula</i> ) ant venom and their clinical relevance: An immunoproteomic approach. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1222-1234.	2.9	13
9	Resistin and NGAL are associated with inflammatory response, endothelial activation and clinical outcomes in sepsis. <i>Inflammation Research</i> , 2017, 66, 611-619.	4.0	40
10	Australian taipan ( <i>Oxyuranus</i> spp.) envenoming: clinical effects and potential benefits of early antivenom therapy – Australian Snakebite Project (ASP-25). <i>Clinical Toxicology</i> , 2017, 55, 115-122.	1.9	36
11	Distinct inflammatory responses differentiate cerebral infarct from transient ischaemic attack. <i>Journal of Clinical Neuroscience</i> , 2017, 35, 97-103.	1.5	8
12	The Australian Snakebite Project, 2005–2015 (ASP-20). <i>Medical Journal of Australia</i> , 2017, 207, 119-125.	1.7	70
13	REstricted Fluid RESuscitation in Sepsis-associated Hypotension (REFRESH): study protocol for a pilot randomised controlled trial. <i>Trials</i> , 2017, 18, 399.	1.6	41
14	Study protocol for a randomised controlled trial of invasive versus conservative management of primary spontaneous pneumothorax. <i>BMJ Open</i> , 2016, 6, e011826.	1.9	31
15	Changes in differential gene expression during a fatal stroke. <i>Journal of Clinical Neuroscience</i> , 2016, 23, 130-134.	1.5	2
16	Incidence of serum sickness after the administration of Australian snake antivenom (ASP-22). <i>Clinical Toxicology</i> , 2016, 54, 27-33.	1.9	19
17	Intracranial haemorrhages associated with venom induced consumption coagulopathy in Australian snakebites (ASP-21). <i>Toxicon</i> , 2015, 102, 8-13.	1.6	21
18	Pilosulins: A review of the structure and mode of action of venom peptides from an Australian ant <i>Myrmecia pilosula</i> . <i>Toxicon</i> , 2015, 98, 54-61.	1.6	36

#	ARTICLE	IF	CITATIONS
19	2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organization Journal, 2015, 8, 32.	3.5	422
20	In reply. Annals of Emergency Medicine, 2015, 65, 124-125.	0.6	1
21	Near-infrared spectroscopy in the assessment of suspected sepsis in the emergency department. Emergency Medicine Journal, 2015, 32, 404-408.	1.0	18
22	Ant venom immunotherapy in Australia: the unmet need. Medical Journal of Australia, 2014, 201, 33-34.	1.7	9
23	Randomized Controlled Trial of Intravenous Antivenom Versus Placebo for Latrodectism: The Second Redback Antivenom Evaluation (RAVE-II) Study. Annals of Emergency Medicine, 2014, 64, 620-628.e2.	0.6	45
24	Clinical research is a priority for emergency medicine but how do we make it happen, and do it well?. EMA - Emergency Medicine Australasia, 2014, 26, 14-18.	1.1	4
25	Comparison of <scp>PIRO</scp>, <scp>SOFA</scp>, and <scp>MEDS</scp> Scores for Predicting Mortality in Emergency Department Patients With Severe Sepsis and Septic Shock. Academic Emergency Medicine, 2014, 21, 1257-1263.	1.8	89
26	Letter to the Editor. Journal of Intensive Care Medicine, 2014, 29, 53-53.	2.8	0
27	Fluid resuscitation for people with sepsis. BMJ, The, 2014, 349, g4611-g4611.	6.0	4
28	Immediate-type hypersensitivity drug reactions. British Journal of Clinical Pharmacology, 2014, 78, 1-13.	2.4	44
29	Modified TIMI risk score cannot be used to identify low-risk chest pain in the emergency department: a multicentre validation study. Emergency Medicine Journal, 2014, 31, 281-285.	1.0	15
30	Genomic Responses during Acute Human Anaphylaxis Are Characterized by Upregulation of Innate Inflammatory Gene Networks. PLoS ONE, 2014, 9, e101409.	2.5	22
31	Sustained Elevation of Resistin, NGAL and IL-8 Are Associated with Severe Sepsis/Septic Shock in the Emergency Department. PLoS ONE, 2014, 9, e110678.	2.5	83
32	Influenza epidemiology, vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in 2013: the Influenza Complications Alert Network. Communicable Diseases Intelligence, 2014, 38, E143-9.	0.5	8
33	Anaphylaxis: Clinical patterns, mediator release, and severity. Journal of Allergy and Clinical Immunology, 2013, 132, 1141-1149.e5.	2.9	220
34	Reply. Journal of Allergy and Clinical Immunology, 2013, 132, 1457.	2.9	0
35	Immune Response to Snake Envenoming and Treatment with Antivenom; Complement Activation, Cytokine Production and Mast Cell Degranulation. PLoS Neglected Tropical Diseases, 2013, 7, e2326.	3.0	92
36	Snakebite in Australia: a practical approach to diagnosis and treatment. Medical Journal of Australia, 2013, 199, 763-768.	1.7	64

#	ARTICLE	IF	CITATIONS
37	Serial multiple biomarkers in the assessment of suspected acute coronary syndrome: multiple infarct markers in chest pain (MIMIC) study. <i>Emergency Medicine Journal</i> , 2013, 30, 149-154.	1.0	9
38	Parenteral antihistamines cause hypotension in anaphylaxis. <i>EMA - Emergency Medicine Australasia</i> , 2013, 25, 92-93.	1.1	27
39	Tiger snake ( <i>Notechis</i> spp) envenoming: Australian Snakebite Project (ASP-13). <i>Medical Journal of Australia</i> , 2013, 198, 194-195.	1.7	7
40	Influenza Vaccine Effectiveness against Hospitalisation with Confirmed Influenza in the 2010-11 Seasons: A Test-negative Observational Study. <i>PLoS ONE</i> , 2013, 8, e68760.	2.5	40
41	Death Adder Envenoming Causes Neurotoxicity Not Reversed by Antivenom - Australian Snakebite Project (ASP-16). <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1841.	3.0	28
42	Ultrarush versus semirush initiation of insect venom immunotherapy: A randomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 162-168.	2.9	44
43	Clinical Effects and Antivenom Dosing in Brown Snake ( <i>Pseudonaja</i> spp.) Envenoming - Australian Snakebite Project (ASP-14). <i>PLoS ONE</i> , 2012, 7, e53188.	2.5	74
44	Tiger snake ( <i>Notechis</i> spp) envenoming: Australian Snakebite Project (ASP-13). <i>Medical Journal of Australia</i> , 2012, 197, 173-177.	1.7	51
45	Critical illness in the emergency department: Lessons learnt from the first 12 months of enrolments in the Critical Illness and Shock Study. <i>EMA - Emergency Medicine Australasia</i> , 2012, 24, 31-36.	1.1	24
46	Myth of tension spontaneous pneumothorax. <i>EMA - Emergency Medicine Australasia</i> , 2012, 24, 117-117.	1.1	0
47	Mediators Released During Human Anaphylaxis. <i>Current Allergy and Asthma Reports</i> , 2012, 12, 33-41.	5.3	28
48	Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: A test-negative case control study. <i>Vaccine</i> , 2011, 29, 7320-7325.	3.8	41
49	Causes of ant sting anaphylaxis in Australia: the Australian Ant Venom Allergy Study. <i>Medical Journal of Australia</i> , 2011, 195, 69-73.	1.7	36
50	FluCAN 2009: initial results from sentinel surveillance for adult influenza and pneumonia in eight Australian hospitals. <i>Medical Journal of Australia</i> , 2011, 194, 169-174.	1.7	32
51	Using Time-Resolved Fluorescence to Measure Serum Venom-Specific IgE and IgG. <i>PLoS ONE</i> , 2011, 6, e16741.	2.5	9
52	Stability of <i>Myrmecia pilosula</i> (Jack Jumper) Ant venom for use in immunotherapy. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 54, 303-310.	2.8	12
53	Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and Severe Hypoglycemia Complicating Type 2 Diabetes: The Fremantle Diabetes Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E696-E700.	3.6	11
54	Changes in serial laboratory test results in snakebite patients: when can we safely exclude envenoming?. <i>Medical Journal of Australia</i> , 2010, 193, 285-290.	1.7	34

#	ARTICLE	IF	CITATIONS
55	Clinical effects of redbellied black snake ( <i>Pseudechis porphyriacus</i> ) envenoming and correlation with venom concentrations: Australian Snakebite Project (ASP 1). Medical Journal of Australia, 2010, 193, 696-700.	1.7	58
56	Human anti-snake venom IgG antibodies in a previously bitten snake-handler, but no protection against local envenoming. Toxicon, 2010, 55, 646-649.	1.6	16
57	Determinants of Severe Hypoglycemia Complicating Type 2 Diabetes: The Fremantle Diabetes Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2240-2247.	3.6	148
58	Envenoming by the roughscaled snake ( <i>Tropidechis carinatus</i> ): a series of confirmed cases. Medical Journal of Australia, 2009, 191, 183-186.	1.7	25
59	Clotting factor replacement and recovery from snake venom-induced consumptive coagulopathy. Intensive Care Medicine, 2009, 35, 1532-1538.	8.2	41
60	Cardiac arrhythmia or movement artefact?. EMA - Emergency Medicine Australasia, 2009, 21, 86-87.	1.1	0
61	Elevated serum cytokines during human anaphylaxis: Identification of potential mediators of acute allergic reactions. Journal of Allergy and Clinical Immunology, 2009, 124, 786-792.e4.	2.9	129
62	Primary outcome measures. BMJ: British Medical Journal, 2009, 339, b3368-b3368.	2.3	1
63	Myrmecia pilosula (Jack Jumper) ant venom: Validation of a procedure to standardise an allergy vaccine. Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 58-65.	2.8	18
64	A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom. British Journal of Clinical Pharmacology, 2008, 65, 139-143.	2.4	26
65	H1-antihistamines for the treatment of anaphylaxis with and without shock. The Cochrane Library, 2007, , CD006160.	2.8	36
66	Efficacy of antivenom against the procoagulant effect of Australian brown snake ( <i>Pseudonaja</i> sp.) venom: In vivo and in vitro studies. Toxicon, 2007, 49, 57-67.	1.6	47
67	The Pathophysiology of Shock in Anaphylaxis. Immunology and Allergy Clinics of North America, 2007, 27, 165-175.	1.9	63
68	Route of administration of redback spider bite antivenom: Determining clinician beliefs to facilitate Bayesian analysis of a clinical trial. EMA - Emergency Medicine Australasia, 2007, 19, 458-463.	1.1	6
69	Proteomic analysis of Myrmecia pilosula (jack jumper) ant venom. Toxicon, 2006, 47, 208-217.	1.6	41
70	Enzyme immunoassays in brown snake ( <i>Pseudonaja</i> spp.) envenoming: Detecting venom, antivenom and venom-antivenom complexes. Toxicon, 2006, 48, 4-11.	1.6	46
71	2. Anaphylaxis: diagnosis and management. Medical Journal of Australia, 2006, 185, 283-289.	1.7	128
72	2. Anaphylaxis: diagnosis and management. Medical Journal of Australia, 2006, 185, 400-400.	1.7	36

#	ARTICLE	IF	CITATIONS
73	High rate of immediate systemic hypersensitivity reactions to tiger snake antivenom. Medical Journal of Australia, 2006, 184, 419-420.	1.7	5
74	Anaphylaxis to bull dog ant and jumper ant stings around Perth, Western Australia. EMA - Emergency Medicine Australasia, 2006, 18, 15-22.	1.1	7
75	Anaphylaxis: Clinical concepts and research priorities. EMA - Emergency Medicine Australasia, 2006, 18, 155-169.	1.1	44
76	Second Symposium on the Definition and Management of Anaphylaxis: Summary Report"Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. Annals of Emergency Medicine, 2006, 47, 373-380.	0.6	497
77	Clinically applicable laboratory end-points for treating snakebite coagulopathy. Pathology, 2006, 38, 568-572.	0.6	27
78	Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Current Opinion in Allergy and Clinical Immunology, 2005, 5, 359-364.	2.3	140
79	Efficacy of ant venom immunotherapy and whole body extracts. Journal of Allergy and Clinical Immunology, 2005, 116, 464-465.	2.9	7
80	Parallel infusion of hydrocortisone ± chlorpheniramine bolus injection to prevent acute adverse reactions to antivenom for snakebites. Medical Journal of Australia, 2004, 180, 428-429.	1.7	7
81	Can serum mast cell tryptase help diagnose anaphylaxis?. EMA - Emergency Medicine Australasia, 2004, 16, 120-124.	1.1	120
82	Clinical features and severity grading of anaphylaxis. Journal of Allergy and Clinical Immunology, 2004, 114, 371-376.	2.9	762
83	Characterisation of major peptides in "jack jumper" ant venom by mass spectrometry. Toxicon, 2004, 43, 173-183.	1.6	57
84	Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania. Journal of Allergy and Clinical Immunology, 2003, 111, 187-192.	2.9	67
85	Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet, The, 2003, 361, 1001-1006.	13.7	129
86	Prevention of anaphylaxis with ant venom immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2003, 3, 511-516.	2.3	19
87	Fatal anaphylaxis following jack jumper ant sting in southern Tasmania. Medical Journal of Australia, 2001, 175, 644-647.	1.7	44
88	Plasma alkalization for tricyclic antidepressant toxicity: A systematic review. EMA - Emergency Medicine Australasia, 2001, 13, 204-210.	1.1	37
89	Migraine precipitated by adenosine. Medical Journal of Australia, 1995, 162, 389-391.	1.7	16